The present disclosure provides compounds that are inhibitors of PIKfyve and/or PI3 kinases, and are therefore useful for the treatment of neurological diseases that are treatable by inhibition of PIKfyve. Also provided are pharmaceutical compositions containing such compounds, and methods of treatment using such compounds.

The present disclosure provides compounds that are inhibitors of PIKfyve and/or PI3 kinases, and are therefore useful for the treatment of neurological diseases that are treatable by inhibition of PIKfyve. Also provided are pharmaceutical compositions containing such compounds, and methods of treatment using such compounds.

A compound is represented by a formula (1). n is 2 to 4, m is 1 to 4, q is 0 to 3, and m+n+q=6; CN is a cyano group; D.sub.1 is a group represented by a formula (2), (3) or (3X), the plurality of D.sub.1 are the same; and Rx is a hydrogen atom or substituent. R.sub.1 to R.sub.8 are each independently a hydrogen atom or substituent. R.sub.31 to R.sub.38 and R.sub.41 to R.sub.48 are each independently a hydrogen atom or substituent; p, px and py are each independently 1 to 4; A to C are each independently a cyclic structure represented by a formula (131) or (132). R.sub.19 and R.sub.20 are each independently a hydrogen atom or substituent. X.sub.1 is a sulfur atom or the like, and * represents a bonding position with a carbon atom of a benzene ring in the formula (1).

##STR00001##

A compound is represented by a formula (1). n is 2 to 4, m is 1 to 4, q is 0 to 3, and m+n+q=6; CN is a cyano group; D.sub.1 is a group represented by a formula (2), (3) or (3X), the plurality of D.sub.1 are the same; and Rx is a hydrogen atom or substituent. R.sub.1 to R.sub.8 are each independently a hydrogen atom or substituent. R.sub.31 to R.sub.38 and R.sub.41 to R.sub.48 are each independently a hydrogen atom or substituent; p, px and py are each independently 1 to 4; A to C are each independently a cyclic structure represented by a formula (131) or (132). R.sub.19 and R.sub.20 are each independently a hydrogen atom or substituent. X.sub.1 is a sulfur atom or the like, and * represents a bonding position with a carbon atom of a benzene ring in the formula (1).

##STR00001##

Pharmaceutical compositions comprising: one or more bromodomain and extra terminal domain (BET) proteolysis targeting chimera (PROTAC) (BET-PROTAC) therapeutic agents or one or more cyclin-dependent kinase 9 (CDK9) PROTAC (CDK9-PROTAC) therapeutic agents; and one or more kinase inhibitors, one or more KRAS inhibitors, or one or more autophagy inhibitors; and methods of treating cancer in a human patient by administering such pharmaceutical compositions are described herein.

##STR00001##

Described herein are PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.

Described herein are PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.

Compounds used as labels with properties comparable to known fluorescent compounds. The compounds are conjugated to proteins and nucleic acids for biological imaging and analysis. Synthesis of the compounds, formation and use of the conjugated compounds, and specific non-limiting examples of each are provided.

Compounds used as labels with properties comparable to known fluorescent compounds. The compounds are conjugated to proteins and nucleic acids for biological imaging and analysis. Synthesis of the compounds, formation and use of the conjugated compounds, and specific non-limiting examples of each are provided.

Compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein: W is O, N—H, N—(C.sub.1-C.sub.10 alkyl) or S; each X is independently CH or N; R.sup.1 is a 5 to 7-membered saturated or unsaturated, optionally substituted heterocycle containing at least 1 heteroatom selected from N or O; R.sup.2 is (LQ).sub.mY; and each R.sup.3 is independently H, C.sub.1-C.sub.10 alkyl, aryl or heteroaryl, are surprisingly found to be inhibitors of PI3K-p110δ, and therefore have utility in therapy.

##STR00001##